The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit returns to Boston in June 2026 as the premier industry forum dedicated to advancing extrahepatic LNP delivery and next-generation targeted lipid nanoparticle technologies. As the field moves beyond liver-focused delivery, achieving precise, selective, tissue-specific targeting remains one of the most critical challenges in genetic medicine. With growing industry validation – including strategic acquisitions by AbbVie and Bristol Myers Squibb – confidence in targeted LNP platforms is accelerating across biopharma.
The summit will also address critical translational challenges, including targeted LNP analytics, scalability, manufacturability, and immunogenicity – key hurdles in advancing extrahepatic delivery toward clinical success. Through 13+ data-driven case studies, 6 interactive workshops, expert panel discussions, and dedicated networking sessions, participants will gain actionable strategies to accelerate development timelines and de-risk clinical progression.
With representation from pioneering organizations across the delivery ecosystem, this meeting provides a unique opportunity to benchmark progress, forge strategic partnerships, and overcome bottlenecks limiting cell-specific LNP performance. Whether optimizing formulation, engineering targeting ligands, refining preclinical models, or preparing for clinical translation, this summit delivers the technical depth required to stay at the forefront of innovation.
Visit Our Website for More Information.